Stockreport

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma [Yahoo! Finance]

Legend Biotech Corporation - American Depositary Shares  (LEGN) 
PDF Results add to the overall survival (OS) benefit recently reported making CARVYKTI ® the first and only cell therapy to significantly extend OS versus standard therapie [Read more]